⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15750904 | 0.78 | — | — | |
| SCHEMBL15750819 | 0.71 | — | — | |
| SCHEMBL270228 | 0.69 | — | — | |
| SCHEMBL1268351 | 0.67 | — | — | |
| SCHEMBL4044501 | 0.67 | — | — | |
| SCHEMBL3129683 | 0.65 | LMNA (0.36) | — | |
| SCHEMBL5569969 | 0.65 | — | — | |
| SCHEMBL11541764 | 0.63 | — | — | |
| SCHEMBL188748 | 0.62 | — | — | |
| SCHEMBL7631831 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879852-B2 | such as (4S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide, used for the treatment of obesity, diabetes, inflammation and erectile dysfunction | LG LIFE SCIENCES LTD. (KR) | 2011-02-01 | — | — | US | claimed |
| US-20090298829-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2009-12-03 | — | — | US | claimed |
| WO-2008007930-A9 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD (KR) | 2009-04-02 | — | — | WO | claimed |
| EP-2041120-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG Life Sciences Ltd. (KR) | 2009-04-01 | — | — | EP | claimed |
| WO-2008007930-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2008-01-17 | — | — | WO | claimed |
| WO-2024108198-A2 | METHODS OF TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-7879852-B2 | such as (4S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide, used for the treatment of obesity, diabetes, inflammation and erectile dysfunction | LG LIFE SCIENCES LTD. (KR) | 2011-02-01 | — | — | US | disclosed |
| US-20090298829-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2009-12-03 | — | — | US | disclosed |
| WO-2008007930-A9 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD (KR) | 2009-04-02 | — | — | WO | disclosed |
| EP-2041120-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG Life Sciences Ltd. (KR) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008007930-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2008-01-17 | — | — | WO | disclosed |